Maximal androgen blockade: Final analysis of EORTC phase III trial 30853

European Urology

Volumn 33, Issue 2, 1998, Pages 144-151

  Denis, L J ^a   Keuppens, F ^a   Smith, P H ^a   Whelan, P ^a   Carneiro de Moura, J L ^a   Newling, D ^a   Bono, A ^a   Sylvester, R ^a  

^a Oncology Centre of Antwerp   (Belgium)

Author keywords

Maximal androgen blockade; Metastatic prostate cancer; Randomized clinical trials

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; GYNECOMASTIA; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TIME OF DEATH; TREATMENT OUTCOME;

EID: 0031907685     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019546     Document Type: Article

References (14)